·¢²¼ÈÕÆÚ£º2020-08-13

½üÄêÀ´£¬Ö²¡¾úÄÍÒ©ÎÊÌâÓú¼ÓÑÏÖØ£¬¶øÇÒĿǰÓÖȱ·¦ÐÂÒ»´ú¿¹ÉúËØÀ´Ó¦¶Ô¶àÖØÄÍÒ©µÄÎÊÌ⣬Òò´ËÁÙ´²ÉϽ÷É÷ʹÓÃÏÖÓеĿ¹ÉúËØ¶ÔÓÚ±£³ÖÆäÓÐЧÐÔÖÁ¹ØÖØÒª¡£Ìرð¶ÔÓÚÄÇЩ×ÔÏÞÐÔ·Çϸ¾ú¸ÐȾºÍ¿µ¸´ÖеÄϸ¾ú¸ÐȾ£¬ÁÙ´²Ò½ÉúÐèÒª¼õÉÙ²»±ØÒªµÄ¿¹ÉúËØÖÎÁÆ¡£PCTÒѾ±»Ö¤Ã÷¿ÉÒÔÓ¦ÓÃÓÚ²»Í¬µÄÁÙ´²³¡¾°À´°ïÖúÖ¸µ¼¿¹ÉúËØÓÃÒ©¡£
PCTÔÚ»ù²ãÒ½ÁÆ»ú¹¹ÁìÓòµÄÓ¦ÓÃ
¶ÔÓÚÄÇЩÁÙ´²±íÏַǽô¼±µÄÉϺôÎüµÀ»òÕßϺôÎüµÀ¸ÐȾ»¼Õߣ¬PCTÓÐÖúÓÚ¼ø±ðÕï¶Ïϸ¾ú»òÕß²¡¶¾¸ÐȾ£¬²¢Ö¸µ¼¿¹ÉúËØÖÎÁÆ¡£
ͨ¹ý¸ÄÉÆÕï¶ÏЧÄÜÀ´°ïÖúÁÙ´²Ò½ÉúÅųý»òÕßÈ·ÈÏϸ¾ú¸ÐȾ
Åųý²»±ØÒªµÄ¿¹ÉúËØÖÎÁÆ
Ò»ÏîÉæ¼°1000¶àÃûÔÚ»ù²ãÒ½ÁÆ»ú¹¹¾ÍÕﻼÕßµÄÑо¿±íÃ÷£¬Ê¹ÓÃPCTÀ´Ö¸µ¼¿¹ÉúËØÖÎÁÆ£¬¿ÉÒÔ¼õÉÙÔ¼60%µÄ¿¹ÉúËØÓÃÒ©¡£¸ü¼ÓÖØÒªµÄÊÇ£¬¼õÉÙÕâЩ¿¹ÉúËØÓÃÒ©Ö®ºó£¬²¢Î´Ôö¼Ó»¼ÕßµÄËÀÍöÂÊ¡¢¸´·¢ÂʺÍÖÎÁÆÊ§°Ü·çÏÕ¡£

ͼ1 »ù²ãÒ½ÁÆ»ú¹¹PCTÖ¸µ¼¿¹ÉúËØÖÎÁÆ[1]
Òò´Ë£¬Èç¹ûPCTµÄ¼ì²âŨ¶ÈµÍÓÚ0.25 ng/mL£¬Ò»°ãÈÏΪ¿ÉÒÔÅųýÏà¹ØµÄϸ¾ú¸ÐȾ£¬²»ÐèÒª¿ªÊ¼¿¹ÉúËØÖÎÁÆ¡£Èç¹û»¼ÕßµÄÁÙ´²Ö¢×´³öÏÖ¶ñ»¯£¬ÐèÒªÔÚ6-24СʱÄÚÔٴμì²âPCTµÄŨ¶È¡£
Èç¹ûPCTµÄ¼ì²âŨ¶È¸ßÓÚ0.25 ng/mL£¬Ï¸¾ú¸ÐȾµÄ¿ÉÄÜÐÔÉÏÉýµÄ»°£¬ÁÙ´²Ò½ÉúÓ¦¸Ã¿¼ÂÇÀ©´óÕï¶ÏÆÀ¹À£¬Ìṩ¿¹ÉúËØÖÎÁÆ£¬²¢ÇÒ½ôÃܹ۲졣
PCT¶ÔÓÚ¼±ÕïºÍסԺ»¼ÕßµÄÓ¦ÓÃ
Ö§Æø¹ÜÑ׺ÍÂýÐÔ×èÈûÐԷβ¡Ôڴ󲿷ÖÇé¿öÏ£¬Ö÷ÒªÓɲ¡¶¾¸ÐȾÒýÆð¡£µ«ÊÇÓÉÓÚ½ö½öÒÀ¿¿ÁÙ´²Ö¢×´ÄÑÒÔÅųýϸ¾úÐÔÖ²¡Ô£¬ºÜ¶à»¼ÕßÒò´Ë½ÓÊÜÁ˹ý¶ÈµÄ¿¹ÉúËØÖÎÁÆ¡£
PCTά³ÖÔڱȽϵ͵ÄŨ¶Èˮƽʱ£¬ÁÙ´²Ò½Éú¿ÉÒÔÔÝÍ£¿¹ÉúËØÖÎÁÆ£¬´ÓÁÙ´²½Ç¶ÈÀ´½øÐнøÒ»²½µÄÆÀ¹À¡£Èç¹û»¼Õß²¡Çé²»Îȶ¨£¬ÐèÒª¿¼ÂÇʹÓÿ¹ÉúËØ¡£Èç¹û»¼Õß²¡ÇéÔÚ¶Ìʱ¼äÄÚ6-12СʱûÓиÄÉÆ£¬ÍƼöÔÙ´Î×öÁÙ´²ÆÀ¹ÀºÍPCT¼ì²â¡£
ͨ¹ý¶Ô1000¶àÎ»Ö§Æø¹ÜÑ׺ÍÂýÐÔ×èÈûÐԷβ¡»¼Õߵĸú×ÙÑо¿£¬Í¨¹ýʹÓÃPCTÀ´Ö¸µ¼¿¹ÉúËØÖÎÁÆ¿ÉÒÔ¼õÉÙ50%Ö§Æø¹ÜÑ×»¼ÕߺÍ65%ÂýÐÔ×èÈûÐԷβ¡»¼ÕߵIJ»±ØÒª¿¹ÉúËØÓÃÒ©£¬Í¬Ê±ÓÖ±£³ÖÁËÏà½üµÄÉú´æÂÊ£¬½µµÍÁ˽øÈëICUµÄ·çÏպͷ¢Éú²¢·¢Ö¢µÄ¸ÅÂÊ£¬ÒÔ¼°´Ù½ø·Î¹¦ÄܵĻָ´¡£
Òò´Ë¶ÔÓÚÖ§Æø¹ÜÑ׺ÍÂýÐÔ×èÈûÐԷβ¡»¼Õߣ¬Èç¹ûÆäPCT¼ì²âŨ¶È½ÏµÍ£¬ÁÙ´²Ö¢×´Ò²²»Ã÷ÏԵϰ£¬²»ÐèÒª½øÐп¹ÉúËØÖÎÁÆ¡£µ«ÊÇ£¬Èç¹ûÂýÐÔ×èÈûÐԷβ¡¼±ÐÔ¼ÓÖØ£¬ÁÙ´²Ò½ÉúÐèÒª¸ù¾ÝÁÙ´²¾Ñé½øÐм°Ê±ÕïÁÆ¡£
PCTÔÚÉçÇø»ñµÃÐÔ·ÎÑ×ÁìÓòµÄÓ¦ÓÃ
Ò»ÏîÉæ¼°2000¶àλÉçÇø»ñµÃÐÔ·ÎÑ×»¼ÕßµÄÑо¿±íÃ÷£¬PCT¶ÔÓÚ¿¹ÉúËØÖÎÁƵľ޴ó¼ÛÖµµÃÒÔ³ä·ÖÌåÏÖ¡£»ùÓÚ´ËÏîÑо¿Êý¾Ý£¬µ±PCT¼ì²âŨ¶È>0.25 ng/mLʱ£¬Ô¤Ê¾×Åϸ¾ú¸ÐȾµÄ¿ÉÄÜÐԺܴ󣬽¨ÒéÁ¢¿Ì½øÐп¹ÉúËØÖÎÁÆ¡£Èç¹ûPCT¼ì²â¿ÉÒÔÔÚ²¡È˾ÍÕïºó1-2СʱÄÚÍê³É£¬×î³õµÄPCTŨ¶ÈÓÐÖúÓÚÁÙ´²Ò½Éú¾ö¶¨ÊÇ·ñ¿ªÊ¼¿¹ÉúËØÖÎÁÆ¡£Èç¹ûPCT¼ì²âÎÞ·¨¼°Ê±½øÐУ¬ÔòÁÙ´²Ò½Éú½«¸ü¶à»ùÓÚÁÙ´²Ö¢×´¾ö¶¨ÊÇ·ñ½øÐп¹ÉúËØÖÎÁÆ¡£»¼Õß½ÓÊÜ¿¹ÉúËØÖÎÁÆÖ®ºó£¬Ã¿¸ôÁ½ÌìÐèÒª¼ì²âPCTŨ¶È£¬ÒÔ±ã¼à²â¿¹ÉúËØÖÎÁÆÁÆÐ§¡£Èç¹û»¼ÕßÁÙ´²Ö¢×´ºÃת£¬²¢ÇÒPCTŨ¶ÈµÍÓÚ0.25 ng/mL£¨»òÕßÖÁÉÙϽµ80-90%£©£¬Ôò¿ÉÒÔ¿¼ÂÇÍ£Ö¹¿¹ÉúËØÖÎÁÆ¡£
Óɴ˿ɼû£¬Í¨¹ýʹÓÃPCTÖ¸µ¼¿¹ÉúËØÖÎÁÆ¿ÉÒÔ¼õÉÙÔ¼40%µÄ¿¹ÉúËØÁƳ̣¬Æ½¾ù¿¹ÉúËØÓÃҩʱ¼ä´Ó11.1Ì콵Ϊ7Ì졣ͬʱԤºóÁ¼ºÃ£¬ÇÒûÓÐÔö¼Ó¸ÐȾ¸´·¢µÄ·çÏÕ¡£Ïà·´£¬Èç¹ûPCTŨ¶È³ÖÐøÉý¸ß£¬Ô¤Ê¾×Åŧ¶¾ÑªÖ¢·¢ÉúµÄ·çÏÕÉÏÉý£¬²¡Çé¿ÉÄܱÈÁÙ´²Ö¢×´±íÏÖ³öÀ´µÄ¸ü¼ÓÑÏÖØ¡£

ͼ2 ÉçÇø»ñµÃÐÔ·ÎÑ×PCTÖ¸µ¼¿¹ÉúËØÖÎÁÆ[1]
±àºó£º
ÔÚĿǰ³£ÓõÄÖî¶àÑ×Ö¢±êÖ¾ÎïÖУ¬PCTÒÔÆä¶ÔÓÚϸ¾ú¸ÐȾµÄ¸ß¶ÈÌØÒìÐÔ±¸ÊܹØ×¢¡£Ò²ÒòÆäÉÏÊöÌØµã£¬ÔÚ´Ë´ÎйڷÎÑ×µÄÕïÁÆ·½°¸ÖÐPCT×÷ΪÅųýϸ¾úÐÔ¸ÐȾµÄÖØÒª¼ì²âÖ¸±êÔÚ¿¹»÷ÒßÇéµÄÒ»Ïß±»¹ã·ºÊ¹Óá£Í¬Ê±ÎÒÃÇӦעÒâµ½£¬PCT»¹³£ÓëIL-6ÁªºÏʹÓ㬴Ӷø½øÒ»²½ÌáÉýÑ×Ö¢¼ì²âÃô¸ÐÐÔ£¬×öµ½“¼ÈÃô¸ÐÓÖÌØÒ씡£
ÁÙ´²ÉÏ£¬PCT ³ýÁË¿ÉÒÔ×÷Ϊ¿¹ÉúËØºÏÀíÓÃÒ©µÄÖ¸µ¼ÏîÄ¿£¬»¹ÊǸ¨ÖúÕï¶Ïϸ¾úºÍŧ¶¾ÑªÖ¢µÄÖØÒªÖ¸±ê£¬ÔÚ¼²²¡µÄ½øÒ»²½·¢Õ¹ÖÐPCTŨ¶ÈµÄÉý¸ß¿ÉÄÜÊÇϸ¾úÖØ¸´¸ÐȾµÄÖ¸Õ÷¡£¿ÉÒÔͨ¹ýPCT¼à¿ØÓиÐȾΣÏÕµÄÖØÖ¢»¼Õß¡£
ÀÖÓãµç¾ºÍƳöµÄPCT¼ì²âÊÔ¼ÁºÐ£¬×îµÍ¼ì²âÏÞ¿É´ï0.02ng/mL; ÏßÐÔ·¶Î§ÔÚ0.04ng/mL~100ng/mL Çø¼äµÄÏßÐÔÏà¹ØÏµÊýr≥0.9900£»Í¬Ê±Òò²ÉÓÃÁ˶ÀÌØµÄÇ׺ÍËØ-ß¹à¤õ¥Ìåϵ£¬ÆäÖØ¸´ÐÔÓëÅú¼ä²îÔ¶ÓÅÓÚÐÐÒµ±ê×¼¡£ÔÚʵ¼ÊµÄÓ¦ÓÃÖеõ½ÁËÁÙ´²Öն˵Ĺ㷺ÈϿɡ£

²Î¿¼ÎÄÏ×£º [1]Schuetz P et al. Clin Infect Dis. 2012;55:651-62. [2]Schuetz P et al: Arch Intern Med 2011;171:1322-31. [3]Long W, Deng X, Zhang Y, et al. PCT guidance for reduction of antibiotic use in low-risk outpatients with community acquired pneumonia. Respirology. 2011;16:819-824. [4]Schuetz P, Chiappa V, Briel et al. Procalcitonin algorithms for antibiotic therapy decisions: a systematic review of randomized controlled trials and recommendations for clinical algorithms. Archives of Internal Medicine 2011, 171(15):1322-1331.





ÊÛºó·þÎñÈÈÏß
4008116695 / 4008116605£¨¹úÄÚ£©
4008087597£¨¹ú¼Ê£©